Sean Moloughney01.07.10
A new human clinical study conducted at Jikei University, Japan, showed a positive relationship between AstaREAL astaxanthin supplementation and cardiovascular health. The study has been accepted for publication by the Atherosclerosis Journal.
With astaxanthin supplementation at a dose of 12 mg per day, this randomized, placebo-controlled study showed a significant decrease in blood serum triglyceride and increase in HDL-cholesterol levels with a corresponding increase in serum adiponectin, independent of age and BMI.
This study joins a growing arsenal of research involving the study of AstaREAL astaxanthin in the area of cardiovascular benefit conducted throughout the world including Japan, Europe and the U.S. Three separate studies have previously been performed at Toyama Medical & Pharmaceutical University, Japan showing a significant decrease in blood pressure with delayed onset of stroke in spontaneous hypertensive rats. Another study conducted at Georgetown University Medical Center, USA also showed a decrease in blood pressure in Zucker Fatty Rats. The studies at both Toyama and Georgetown also explored the mechanism of action for blood pressure reduction.
A human blood rheology study, performed in Japan, demonstrated that AstaREAL astaxanthin supplementation significantly increased peripheral capillary blood flow. At Linkoping University, Sweden, astaxanthin was studied in hyperlipidaemic rabbits for its ability to decrease macrophage infiltration, apoptosis and vulnerability in atheroma. In another human clinical performed in Finland using a randomized double-blind study design, AstaREAL astaxanthin supplementation was investigated for its ability to reduce lipid peroxidation in healthy non-smoking men, aged 19-33 years.
Finally, a study designed to investigate the mental and physical effects of astaxanthin supplementation on subjects with increased oxidative stress burden was performed at Doshisha University, Japan on 20 healthy postmenopausal women. After eight weeks of AstaREAL astaxanthin supplementation ABI (ankle brachial pressure index) significantly increased (suggesting reduced lower limb vascular resistance) and a significant reduction in both systolic and diastolic blood pressure was shown.
With astaxanthin supplementation at a dose of 12 mg per day, this randomized, placebo-controlled study showed a significant decrease in blood serum triglyceride and increase in HDL-cholesterol levels with a corresponding increase in serum adiponectin, independent of age and BMI.
This study joins a growing arsenal of research involving the study of AstaREAL astaxanthin in the area of cardiovascular benefit conducted throughout the world including Japan, Europe and the U.S. Three separate studies have previously been performed at Toyama Medical & Pharmaceutical University, Japan showing a significant decrease in blood pressure with delayed onset of stroke in spontaneous hypertensive rats. Another study conducted at Georgetown University Medical Center, USA also showed a decrease in blood pressure in Zucker Fatty Rats. The studies at both Toyama and Georgetown also explored the mechanism of action for blood pressure reduction.
A human blood rheology study, performed in Japan, demonstrated that AstaREAL astaxanthin supplementation significantly increased peripheral capillary blood flow. At Linkoping University, Sweden, astaxanthin was studied in hyperlipidaemic rabbits for its ability to decrease macrophage infiltration, apoptosis and vulnerability in atheroma. In another human clinical performed in Finland using a randomized double-blind study design, AstaREAL astaxanthin supplementation was investigated for its ability to reduce lipid peroxidation in healthy non-smoking men, aged 19-33 years.
Finally, a study designed to investigate the mental and physical effects of astaxanthin supplementation on subjects with increased oxidative stress burden was performed at Doshisha University, Japan on 20 healthy postmenopausal women. After eight weeks of AstaREAL astaxanthin supplementation ABI (ankle brachial pressure index) significantly increased (suggesting reduced lower limb vascular resistance) and a significant reduction in both systolic and diastolic blood pressure was shown.